SCHEMBL9967917

SCHEMBL9967917

CCC(=O)Cc1c[nH]c2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.66
MEN1 O00255 7/20 0.64
KMT2A Q03164 7/20 0.64
MAPT P10636 6/20 0.64
KDM4E B2RXH2 4/20 0.64
ALDH1A1 P00352 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
HPGD P15428 2/20 0.64
LMNA P02545 2/20 0.60
SLC6A2 P23975 1/20 0.60
FNTA P49354 1/20 0.60
FNTB P49356 1/20 0.60
APAF1 O14727 1/20 0.55
POLB P06746 1/20 0.55
RECQL P46063 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CYP3A4 P08684 2/20 0.55
AHR P35869 1/20 0.55
GPR84 Q9NQS5 1/20 0.55
TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30354024 1.00 PKM (0.66) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL21479833 0.90 MAPT (0.72) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL29407882 0.90 MAPT (0.72) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL15281778 0.85 MAPT (0.66) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL16982043 0.84 MTNR1A (0.62) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL10031559 0.84 MAPT (0.62) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL2796753 0.83 MAPT (0.64) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL468399 0.83 MEN1 (0.68) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL29629485 0.83 MEN1 (0.68) PKMMEN1KMT2AMAPTKDM4E
SCHEMBL28762416 0.82 MAPT (0.67) PKMMEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442971-B1 ESTROGEN RECEPTOR MODULATORS RECURIUM IP HOLDINGS LLC (US) 2024-09-25 EP disclosed
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. 2023-04-20 US disclosed
CN-112679495-B Estrogen receptor modulators 里科瑞尔姆IP控股有限责任公司 2023-03-28 CN disclosed
CN-113717170-A Estrogen receptor modulators 里科瑞尔姆IP控股有限责任公司 2021-11-30 CN disclosed
US-20210348139-A1 BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2021-11-11 US disclosed
US-20210330651-A1 ESTROGEN RECEPTOR MODULATORS RECURIUM IP HOLDINGS, LLC 2021-10-28 US disclosed
CN-109311870-B Estrogen receptor modulators 里科瑞尔姆IP控股有限责任公司 2021-09-21 CN disclosed
US-11065233-B2 Estrogen receptor modulators RECURIUM IP HOLDINGS, LLC (US) 2021-07-20 US disclosed
US-11065234-B2 Estrogen receptor modulators RECURIUM IP HOLDINGS, LLC (US) 2021-07-20 US disclosed
CN-112745316-A Estrogen receptor modulators 里科瑞尔姆IP控股有限责任公司 2021-05-04 CN disclosed
US-9139821-B2 Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs CODEXIS, INC. (US) 2015-09-22 US disclosed
US-9139821-B2 Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs CODEXIS, INC. (US) 2015-09-22 US disclosed
US-20150072383-A1 BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2015-03-12 US disclosed
US-20150072383-A1 BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2015-03-12 US disclosed
WO-2013142770-A1 BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS CODEXIS, INC. (US) 2013-09-26 WO disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
US-20120152356-A1 PHOTOELECTRIC CONVERSION ELEMENT AND DYE-SENSITIZED SOLAR CELL KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2012-06-21 US disclosed
US-20100158862-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
EP-1286966-B1 4-AMINOPIPERIDINE DERIVATIVES AND THEIR USE AS MEDICINE SOD CONSEILS RECH APPLIC (FR) 2008-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11065233-B2 Estrogen receptor modulators ESR2, GPER1, ESRRG PKM 1904/4885MEN1 3935/4885KMT2A 3296/4885
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK2AP2 PKM 1158/4885MEN1 3029/4885KMT2A 1017/4885
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA PKM 4499/4885MEN1 4630/4885KMT2A 1656/4885
US-20100158862-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS PKM 3874/4885MEN1 4867/4885KMT2A 4516/4885
US-20210330651-A1 ESTROGEN RECEPTOR MODULATORS ESR2, GPER1, ESRRG PKM 1904/4885MEN1 3935/4885KMT2A 3296/4885
US-11065234-B2 Estrogen receptor modulators ESR2, GPER1, ESRRG PKM 1904/4885MEN1 3935/4885KMT2A 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.